Skip to Main Content
Table 1

Proportions of patients with fast eGFR decline (mean annual decrease of eGFR ≥3 mL/min/1.73 m2/year), by treatment arm

Baseline to 4 years6 months to 4 years
DapagliflozinPlaceboP valueDapagliflozinPlaceboP value
Subgroupn/N (%)n/N (%)n/N (%)n/N (%)
Overall 2,724/8,096 (33.7) 2,961/8,012 (37.0) <0.0001 2,041/7,603 (26.8) 2,747/7,409 (37.1) <0.0001 
Demographic characteristics       
 Age, <65 years 1,436/4,380 (32.8) 1,560/4,355 (35.8) 0.0028 1,104/4,149 (26.1) 1,417/4,041 (35.1) <0.0001 
 Age, ≥65 years 1,288/3,716 (34.7) 1,401/3,657 (38.3) 0.0011 937/3,454 (27.1) 1,330/3,368 (39.5) <0.0001 
Medical History       
 Duration of diabetes (years)       
  ≤10 1,298/4,030 (32.2) 1,441/4,053 (35.6) 0.0015 1,021/3,805 (26.8) 1,355/3,756 (36.1) <0.0001 
  >10 1,426/4,066 (35.0) 1,520/3,958 (38.4) 0.0020 1,020/3,798 (26.9) 1,392/3,653 (38.1) <0.0001 
 History of hypertension       
  Yes 2,509/7,327 (34.2) 2,693/7,150 (37.7) <0.0001 1,865/6,890 (27.1) 2,512/6,604 (38.0) <0.0001 
  No 215/769 (28.0) 268/862 (31.1) 0.1657 176/713 (24.7) 235/805 (29.2) 0.0478 
Laboratory and clinical measurements       
 Baseline HbA1c       
  <9%/75 mmol/mol 1,877/5,940 (31.6) 2,128/5,994 (35.5) <0.0001 1,425/5,600 (25.5) 1,996/5,567 (35.9) <0.0001 
  ≥9%/75 mmol/mol 847/2,154 (39.3) 833/2,014 (41.4) 0.1800 616/2,001 (30.8) 750/1,839 (40.8) <0.0001 
 Baseline eGFR (mL/min/1.73m2      
  <60 144/555 (26.0) 162/592 (27.4) 0.5869 122/493 (24.8) 193/532 (36.3) <0.0001 
  60 to <90 1,345/3,614 (37.2) 1,472/3,636 (40.5) 0.0043 1,070/3,395 (31.5) 1,452/3,358 (43.2) <0.0001 
  ≥90 1,235/3,927 (31.5) 1,327/3,784 (35.1) 0.0007 848/3,714 (22.8) 1,102/3,519 (31.3) <0.0001 
 Baseline UACR (mg/g)       
  Below detectable to <15 1,207/4,298 (28.1) 1,316/4,261 (30.9) 0.0045 954/4,061 (23.5) 1,288/3,999 (32.2) <0.0001 
  15 to <30 416/1,212 (34.3) 446/1,209 (36.9) 0.1871 303/1,144 (26.5) 419/1,106 (37.9) <0.0001 
  ≥30 to ≤300 757/1,898 (39.9) 800/1,864 (42.9) 0.0588 548/1,779 (30.8) 718/1,712 (41.9) <0.0001 
  >300 294/548 (53.7) 345/528 (65.3) <0.0001 201/496 (40.5) 272/461 (59.0) <0.0001 
KDIGO risk categories       
 Low risk 1,562/5,204 (30.0) 1,703/5,150 (33.1) 0.0008 1,197/4,929 (24.3) 1,616/4,814 (33.6) <0.0001 
 Moderate risk 769/2,001 (38.4) 803/1,965 (40.9) 0.1170 569/1,877 (30.3) 737/1,807 (40.8) <0.0001 
 High/very high risk 343/751 (45.7) 401/747 (85.7) 0.0019 239/673 (35.5) 344/657 (52.4) <0.0001 
Cardiovascular drugs—ACEi/ARB       
 Yes 2,244/6,579 (34.1) 2,475/6,529 (37.9) <0.0001 1,686/6,197 (27.2) 2,292/6,038 (38.0) <0.0001 
 No 480/1,517 (31.6) 486/1,483 (32.8) 0.5078 355/1,406 (25.3) 455/1,371 (33.2) <0.0001 
Baseline to 4 years6 months to 4 years
DapagliflozinPlaceboP valueDapagliflozinPlaceboP value
Subgroupn/N (%)n/N (%)n/N (%)n/N (%)
Overall 2,724/8,096 (33.7) 2,961/8,012 (37.0) <0.0001 2,041/7,603 (26.8) 2,747/7,409 (37.1) <0.0001 
Demographic characteristics       
 Age, <65 years 1,436/4,380 (32.8) 1,560/4,355 (35.8) 0.0028 1,104/4,149 (26.1) 1,417/4,041 (35.1) <0.0001 
 Age, ≥65 years 1,288/3,716 (34.7) 1,401/3,657 (38.3) 0.0011 937/3,454 (27.1) 1,330/3,368 (39.5) <0.0001 
Medical History       
 Duration of diabetes (years)       
  ≤10 1,298/4,030 (32.2) 1,441/4,053 (35.6) 0.0015 1,021/3,805 (26.8) 1,355/3,756 (36.1) <0.0001 
  >10 1,426/4,066 (35.0) 1,520/3,958 (38.4) 0.0020 1,020/3,798 (26.9) 1,392/3,653 (38.1) <0.0001 
 History of hypertension       
  Yes 2,509/7,327 (34.2) 2,693/7,150 (37.7) <0.0001 1,865/6,890 (27.1) 2,512/6,604 (38.0) <0.0001 
  No 215/769 (28.0) 268/862 (31.1) 0.1657 176/713 (24.7) 235/805 (29.2) 0.0478 
Laboratory and clinical measurements       
 Baseline HbA1c       
  <9%/75 mmol/mol 1,877/5,940 (31.6) 2,128/5,994 (35.5) <0.0001 1,425/5,600 (25.5) 1,996/5,567 (35.9) <0.0001 
  ≥9%/75 mmol/mol 847/2,154 (39.3) 833/2,014 (41.4) 0.1800 616/2,001 (30.8) 750/1,839 (40.8) <0.0001 
 Baseline eGFR (mL/min/1.73m2      
  <60 144/555 (26.0) 162/592 (27.4) 0.5869 122/493 (24.8) 193/532 (36.3) <0.0001 
  60 to <90 1,345/3,614 (37.2) 1,472/3,636 (40.5) 0.0043 1,070/3,395 (31.5) 1,452/3,358 (43.2) <0.0001 
  ≥90 1,235/3,927 (31.5) 1,327/3,784 (35.1) 0.0007 848/3,714 (22.8) 1,102/3,519 (31.3) <0.0001 
 Baseline UACR (mg/g)       
  Below detectable to <15 1,207/4,298 (28.1) 1,316/4,261 (30.9) 0.0045 954/4,061 (23.5) 1,288/3,999 (32.2) <0.0001 
  15 to <30 416/1,212 (34.3) 446/1,209 (36.9) 0.1871 303/1,144 (26.5) 419/1,106 (37.9) <0.0001 
  ≥30 to ≤300 757/1,898 (39.9) 800/1,864 (42.9) 0.0588 548/1,779 (30.8) 718/1,712 (41.9) <0.0001 
  >300 294/548 (53.7) 345/528 (65.3) <0.0001 201/496 (40.5) 272/461 (59.0) <0.0001 
KDIGO risk categories       
 Low risk 1,562/5,204 (30.0) 1,703/5,150 (33.1) 0.0008 1,197/4,929 (24.3) 1,616/4,814 (33.6) <0.0001 
 Moderate risk 769/2,001 (38.4) 803/1,965 (40.9) 0.1170 569/1,877 (30.3) 737/1,807 (40.8) <0.0001 
 High/very high risk 343/751 (45.7) 401/747 (85.7) 0.0019 239/673 (35.5) 344/657 (52.4) <0.0001 
Cardiovascular drugs—ACEi/ARB       
 Yes 2,244/6,579 (34.1) 2,475/6,529 (37.9) <0.0001 1,686/6,197 (27.2) 2,292/6,038 (38.0) <0.0001 
 No 480/1,517 (31.6) 486/1,483 (32.8) 0.5078 355/1,406 (25.3) 455/1,371 (33.2) <0.0001 
Close Modal

or Create an Account

Close Modal
Close Modal